The study of tributyrin supplementation in Parkinson Disease

illustrative image

Nicolaas Bohnen, MD, PhD is starting a new clinical trial of Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation.

Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease

The overarching goal of this small exploratory open-label pilot study is to explore PET changes (butyrate, glucose) and cognition (MoCa) before and after open-label treatment with the short-chain fatty acid (SCFA) prodrug tributyrin in a small pilot study in PD (n=8) and normal control older adults (n=2). Positive findings in this small exploratory pilot trial may support target engagement study of SCFA supplementation in normal adults and PD.

The clinical trial started in July 1, 2022 and will continue throughout January 2024.

PET metabolism will be primary outcome measure. after open-label treatment with the SCFA prodrug tributyrin in patients with PD and normal controls.

For more details:

Clinical Research News

Upcoming Clinical Trials